Trial Profile
Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ASP 7991 (Primary) ; Cinacalcet
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 26 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 May 2014 New trial record